Overview

TATE and KN046 in MCRC

Status:
TERMINATED
Trial end date:
2025-01-09
Target enrollment:
Participant gender:
Summary
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc fusion protein injection) in patients with liver metastases from colorectal cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Zhejiang Raygene Pharmaceuticals Co., Ltd
Collaborator:
Jiangsu Alphamab Biopharmaceuticals Co., Ltd